guest ::
| Home > Publications database > Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses. > print |
| Home > Publications database > Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses. > print |
| 001 | 182439 | ||
| 005 | 20240229145719.0 | ||
| 024 | 7 | _ | |a 10.1186/s13643-022-02105-0 |2 doi |
| 024 | 7 | _ | |a pmid:36329524 |2 pmid |
| 024 | 7 | _ | |a altmetric:138038539 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-02648 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Fuchs, Juri |b 0 |
| 245 | _ | _ | |a Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses. |
| 260 | _ | _ | |a London |c 2022 |b Biomed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667814880_20813 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Commentary |
| 520 | _ | _ | |a Rare liver lesions and diseases have seldomly aroused major interest of researchers. For most guidelines, presumably similar clinical conditions are pooled without detailed investigations of singularities that they present.A multidisciplinary project aiming to establish evidence-based therapies for rare liver diseases has been founded. A series of systematic reviews and meta-analyses will be the starting point for a structured development of guidelines for rare conditions of the liver affecting pediatric and adult populations. The novel approach will be focusing on case reports and small patient series with distinct rare liver diseases without pooling several presumably acceptably similar conditions. Thus, a vital resource of information will be utilized, which has been largely neglected hitherto.Highly specific recommendations based on highest available evidence will therefore be developed for specific conditions, advancing the individualized medicine approach for the afflicted patients. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Evidence-based medicine |2 Other |
| 650 | _ | 7 | |a Meta-analysis |2 Other |
| 650 | _ | 7 | |a RELIVE |2 Other |
| 650 | _ | 7 | |a Rare liver disease |2 Other |
| 650 | _ | 7 | |a Rare liver tumors |2 Other |
| 650 | _ | 7 | |a Systematic reviews |2 Other |
| 700 | 1 | _ | |a Murtha-Lemekhova, Anastasia |b 1 |
| 700 | 1 | _ | |a Pfeiffenberger, Jan |b 2 |
| 700 | 1 | _ | |a Fichtner, Alexander |b 3 |
| 700 | 1 | _ | |a Günther, Patrick |b 4 |
| 700 | 1 | _ | |a Halama, Niels |0 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601 |b 5 |u dkfz |
| 700 | 1 | _ | |a Mayer, Philipp |b 6 |
| 700 | 1 | _ | |a Hornuss, Daniel |b 7 |
| 700 | 1 | _ | |a Klotz, Rosa |b 8 |
| 700 | 1 | _ | |a Probst, Pascal |b 9 |
| 700 | 1 | _ | |a Hoffmann, Katrin |b 10 |
| 700 | 1 | _ | |a Initiative, RELIVE |b 11 |e Collaboration Author |
| 773 | _ | _ | |a 10.1186/s13643-022-02105-0 |g Vol. 11, no. 1, p. 235 |0 PERI:(DE-600)2662257-9 |n 1 |p 235 |t Systematic Reviews |v 11 |y 2022 |x 2046-4053 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:182439 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2020-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-08-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-08-29 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2020-08-29 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-02-14T16:19:49Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-02-14T16:19:49Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Open peer review |d 2021-02-14T16:19:49Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-He78)D240-20160331 |k D240 |l Translationale Immuntherapie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D240-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|